What is Vericel Financial Strength?
Vericel has the Financial Strength Rank of 7.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Vericel did not have earnings to cover the interest expense.
Vericel's debt to revenue ratio for the quarter that ended in Mar. 2024 was 0.45.
As of today, Vericel's Altman Z-Score is 10.94.
Competitive Comparison of Vericel's Financial Strength
For the Biotechnology subindustry, Vericel's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vericel's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vericel's Financial Strength distribution charts can be found below:
* The bar in red indicates where Vericel's Financial Strength falls into.
Vericel Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Vericel's Interest Expense for the
months ended in Mar. 2024 was $-0.2 Mil. Its Operating Income for the
months ended in Mar. 2024 was $-5.5 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $86.1 Mil.
Vericel's Interest Coverage for the quarter that ended in Mar. 2024 is
| Vericel did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Vericel's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Vericel has a Z-score of 10.94, indicating it is in Safe Zones. This implies the Z-Score is strong.
Good Sign:
Altman Z-score of 10.94 is strong.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vericel (Vericel) Business Description
Traded in Other Exchanges
Address
64 Sidney Street, Cambridge, MA, USA, 02139
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in advanced therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.
Executives
| Dominick Colangelo |
director, officer: President and CEO |
1000 WINTER ST., SUITE 2200, WALTHAM MA 02451 |
| Zerbe Robert L Md |
director |
|
| Paul K Wotton |
director |
C/O ANTARES PHARMA, INC., 707 EAGLEVIEW BOULEVARD, SUITE 414, EXTON PA 19341 |
| Sean C. Flynn |
officer: SVP, General Counsel |
C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139 |
| Michael Halpin |
officer: Chief Operating Officer |
C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139 |
| Jonathan Mark Hopper |
officer: Chief Medical Officer |
64 SIDNEY STREET, CAMBRIDGE MA 02139 |
| Jonathan Siegal |
officer: Principal Accounting Officer |
C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139 |
| Lisa Wright |
director |
C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139 |
| Mara Joseph Anthony Jr |
officer: Chief Financial Officer |
C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139 |
| Steven C Gilman |
director |
110 HARTWELL AVENUE, LEXINGTON MA 02421 |
| Sandra Pennell |
officer: VP and Corporate Controller |
C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139 |
| Gerard J Michel |
officer: CFO & VP , Corp. Development |
420 CHIPETA WAY, SALT LAKE CITY UT 84108 |
| Daniel Orlando |
officer: Chief Operating Officer |
P.O. BOX 376, ANN ARBOR MI 48105 |
| Alan L Rubino |
director |
PO BOX 376, LOBBY L., ANN ARBOR MI 48105 |
| Consonance Capital Management Lp |
10 percent owner |
1370 AVENUE OF THE AMERICAS, SUITE 3301, NEW YORK NY 10019 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VCEL has been successfully added to your